Chart-Typ:
Zeitraum:
| Chimerix, Inc.: Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End | Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday... ► Artikel lesen |
| Chimerix, Inc.: Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards... ► Artikel lesen |
| Chimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting | DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients... ► Artikel lesen |
| Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2024 Financial Results | Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified... ► Artikel lesen |
| Purple Biotech Ltd.: Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer ... | CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell... ► Artikel lesen |
| Purple Biotech Ltd.: Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 | High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC)... ► Artikel lesen |
| Momentus Inc. Announces Reverse Stock Split | SAN JOSE, Calif.--(BUSINESS WIRE)--Momentus Inc. (NASDAQ: MNTS) ("Momentus" or the "Company"), a U.S. commercial space company that offers satellite buses, transportation and other in-space infrastructure... ► Artikel lesen |
| Momentus Receives Nasdaq Notice of a Delisting Determination | SAN JOSE, Calif.--(BUSINESS WIRE)--Momentus Inc. (NASDAQ: MNTS) ("Momentus" or the "Company"), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure... ► Artikel lesen |
| Momentus Inc.: Momentus Enters Into Collaboration Agreement with Lodestar Space for Robotics in Space | Momentus Inc. (NASDAQ: MNTS) ("Momentus" or the "Company"), a provider of satellite buses and in-space infrastructure services including in-space transportation, hosted payloads, and other in-orbit... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO ENERGY CORPORATION finden Sie auf Wallstreet Online.
